Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy

Why did Tesla's stock soar after robotaxi launch? How will US-Iran conflict impact oil prices? What caused Kroger to announce store closures? Why are Fed officials signaling potential rate cuts? How is the Iran strike affecting global markets? What’s behind Compass suing Zillow over listings? Why is Fiserv entering the stablecoin market?

Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy

benzinga.com/news/health-care/25/06/46058344/mercks-hypertension-drug-cuts-clinical-worsening-risk-in-over-70-of-patients-on-double-backgroun

Merck & Co., Inc. (NYSE:MRK) on Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH)…

This story appeared on benzinga.com, 2025-06-23 17:16:49.